FDA approves Ryzumvi (phentolamine ophthalmic solution) for pharmacologically-induced mydriasis

The U.S. Food and Drug Administration has approved Ryzumvi (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists or parasympatholytic agents, according to a company press release. Ryzumvi is expected to be commercially available in the U.S. in the first half of 2024. Ryzumvi was...